{
    "clinical_study": {
        "@rank": "13278", 
        "arm_group": {
            "arm_group_label": "Kiklin group"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this survey is to evaluate the safety and efficacy of long-term use of\n      Kiklin\u00ae Capsules in actual clinical settings."
        }, 
        "brief_title": "Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency", 
                "Hyperphosphatemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Bixalomer is administered at initial oral dosage of 500 mg three times a day just before a\n      meal. The dosage can be adjusted based on symptoms and serum phosphorus level."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Chronic renal failure patients with hyperphosphataemia receiving hemodialysis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Chronic renal failure patients with hyperphosphataemia receiving hemodialysis"
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901107", 
            "org_study_id": "KIK001"
        }, 
        "intervention": {
            "arm_group_label": "Kiklin group", 
            "description": "oral", 
            "intervention_name": "Kiklin capsules", 
            "intervention_type": "Drug", 
            "other_name": [
                "bixamer", 
                "ASP1585", 
                "ILY101", 
                "AMG223"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Hyperphosphatemia", 
            "Hemodialysis", 
            "CKD (chronic kidney disease)", 
            "ASP1585"
        ], 
        "lastchanged_date": "July 15, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kinki", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyusyu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Touhoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)\u00ae Capsules in Patients With Hyperphosphataemia Receiving Hemodialysis", 
        "overall_contact": {
            "email": "clinicaltrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Use Central Contact", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety assessed by the incidence of adverse events, physical exam and lab-tests", 
            "safety_issue": "No", 
            "time_frame": "for one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901107"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum phosphate level", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1, 2, 3, 6, 12 months after administration"
            }, 
            {
                "measure": "Serum calcium level", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1, 2, 3, 6, 12 months after administration"
            }, 
            {
                "measure": "Intact PTH (parathyroid hormone) level", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1, 2, 3, 6, 12 months after administration"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}